newsfilter
← Latest News
GlobeNewswire·

Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results

On track to proceed with enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI in H2 2022 On track to submit IND for FIN-211 in children with autism and significant GI symptoms in Q4 2022 Additional results from PRISM-EXT Phase 2 trial of CP101